Description
Created On: 2020-07-15
Record Count: 12
Primary Industries
- Drugs
- Disease
- Therapeutic
- Gastrointestinal
- Pain
- Pharmaceuticals
- Diagnostic
- Drug Discovery
- Cancer
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279342
Combination Product means any Product that contains the Compound as an active ingredient together with one or more other active ingredients and is sold for a single invoiced price, e.g., where the Compound is packaged for sale together with a second compound or biologic as an active ingredient (either as a single fixed dose or as separate doses).
Compound means R-methyinaltrexoun (R-MNTX) which is chemically defined as morphinanium, 17R, 17-(cyclopropylmethyl)-4, 5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5a)-(9C1), and its pharmacologically acceptable salts, together with their solvates, hydrates, hemihydrates, metabolites, pro-drugs, esters, and if applicable, any isomers or racemates thereof, but excluding any of the foregoing olecules whose primary mechanism of action is as an opioid agonist. The “Compound†does not include the Excluded Molecules.
Licensor Patent Rights means any Patent Right Controlled by Licensor or its Affiliates as of the Effective Date or at any time during the Term that relates to, claims, or if issued, would be infringed by an unlicensed Third Party’s manufacture, use, sale, importation, Development or Commercialization of the Compound, or any Product; provided, however, that if a Third Party becomes an Affiliate of Licensor pursuant to a transaction or series of related transactions as a result of which such Third Party is able to elect a majority of the members of the board of directors of Licensor (or its successor company) or any of its “controlling Affiliates†(as defined in this agreement) (Licensor Change of Control), “Licensor Patent Rights†will not include any Patent Rights that were Controlled by such Third Party prior to the completion of such transaction or series of related transactions. Licensor Patent Rights are identified as:
4,719,215 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
4,861,781 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
5,102,887 – Method for reducing emesis and nausea induced by the administration of an emesis causing agent
Joint Patent Rights means any Patent Rights related to any invention, development or discovery made or created in the course of the Collaboration jointly by (i) employees or agents of Licensor or any of its Affiliates, and (ii) employees or agents of Licensee or any of its Affiliates, as determined in accordance with this agreement (Inventorship).
Licensor Technology means the Licensor Know-How and the Licensor Patent Rights.
Joint Technology means the Joint Know-How and the Joint Patent Rights.
To relieve pain, narcotic medications such as morphine activate specific opioid receptors located in the central nervous system – the brain and spinal cord. Opioids, however, also interact with these receptors outside of the central nervous system, resulting in side effects, which can be debilitating, including constipation, urinary retention and severe itching. MNTX is designed to block peripheral opioid receptors whose activation causes these side effects. As MNTX does not cross the blood-brain barrier, it does not interfere with brain-centered pain relief.
IPSCIO Record ID: 279343
4,176,186 – Quaternary derivatives of noroxymorphone which relieve intestinal immobility
Compound shall mean N-methylnaltrexone having the chemical structure C21H26BrNO.
IPSCIO Record ID: 111868
Phase A is for completing studies sufficient to establish the therapeutic index of the Compound and of whether Licensee intends to initiate Phase B. Phase B is for developing and commercializing the Compound or Product.
ADL 8-2698 is a peripherally-acting, gastrointestinal tract-restricted mu opioid receptor antagonist. ADL 8-2698 is for treatment of narcotic bowel dysfunction.
Narcotic bowel syndrome (NBS) is a subset of opioid bowel dysfunction that is characterized by chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics. As a result of the undesired action of opioids on the gastrointestinal (GI) tract, patients receiving opioid medication for chronic pain often experience opioid-induced bowel dysfunction (OBD), the most common and debilitating symptom of which is constipation.
Licensee are developing orally-administered ADL 8-2698 to block the adverse gastrointestinal side effects of narcotics without blocking the beneficial analgesic effects. These gastrointestinal side effects include narcotic bowel dysfunction, ileus, which is delayed recovery of bowel function after surgery, and nausea.
IPSCIO Record ID: 266852
Licensor grants the exclusive right to use and to disclose to Third Parties all regulatory and clinical documentation and data developed by or on behalf of Licensor in the Territory in connection with this Agreement and required to be disclosed to Licensee under this Agreement, as reasonably necessary or desirable in connection with the development and commercialization of pharmaceutical products in the Field in the Rest of World or outside the Field throughout the world.
Licensor agrees to negotiate in good faith with Licensee concerning the terms of a license under the Licensor Patents and the Licensor Know-How covering the composition of matter or the use of the Terminated Compounds, to permit Licensee to research, develop, make, have made, import, use, sell and offer for sale the Terminated Compounds outside the Field throughout the world.
Licensor grants an exclusive, including with regard to Licensor, right and license in the Rest of World under the Licensor Patents and the Licensor Know-How and under Licensors rights in the Joint Patents, Joint KnowHow and Joint Research Technology, to research and develop, and to make, have made, import, use, sell and offer for sale pharmaceutical products, including Licensed Products, in the Field.
Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound. Development Compound means any Collaboration Compound that has
been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.
The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.
Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.
Licensee possesses proprietary technology and know-how related to the discovery, identification and synthesis of nicotinic agonists and has identified and applied for patents on certain nicotinic agonist compounds.
IPSCIO Record ID: 26279
Opioid analgesics provide pain relief by stimulating opioid receptors located in the central nervous system. There are, however, opioid receptors throughout the body, including the GI tract. By binding to the receptors in the GI tract, opioid analgesics can slow gut motility and disrupt normal GI function that allows for the passage, absorption and excretion of ingested solid materials. This disruption can cause patients to experience significant discomfort and abdominal pain and may result in their reducing or eliminating their pain medication.
Entereg is a small molecule, mu-opioid receptor antagonist intended to block the adverse side effects of opioid analgesics on the GI tract without affecting analgesia. We are developing Entereg for both acute and chronic conditions.
IPSCIO Record ID: 271161
For the Commercialization License, Licensor grants to Licensee and its Affiliates a co-exclusive, with Licensor, right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology, and under Licensors rights in the Joint Know-How, Joint Research Technology and Joint Patents, to make, have made, import and use Licensed Products for use in the Field; and an exclusive, including with regard to Licensor right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology, and under Licensors rights in the Joint Know-How, Joint Research Technology and Joint Patents, to sell and offer for sale Licensed Products for use in the Field.
Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound. Development Compound means any Collaboration Compound that has been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.
The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.
Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.
Ulcerative colitis is a long-term condition that results in inflammation and ulcers of the colon and rectum.
IPSCIO Record ID: 260459
Licensor grants a license to use the Licensor House Marks in connection with the Commercialization of Licensor Products in the Field of Use in the Territory.
Licensor grants an option for a period of twenty-four months the Japan Option Period after the Effective Date to include Japan in the Territory to Licensee.
Esomeprazole means that certain pharmaceutical compound with the name (5-methoxy-2-{(S)-[ ( 4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl }-1 H-benzimidazole ), including any salts, hydrates, solvates, polymorphs and tautomers thereof.
Naproxen means that certain pharmaceutical compound with the chemical name (S)-6-methoxy-(alpha)-methyl-2-naphthaleneaceti,c acid, including any esters, salts, hydrates, solvates and polymorphs thereof.
The patent is for Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs.
IP relates to the sublicenses’s proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet. Naproxen is used to relieve pain from various conditions such as headache, muscle aches, tendonitis, dental pain, and menstrual cramps. It also reduces pain, swelling, and joint stiffness caused by arthritis, bursitis, and gout attacks. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID).
IPSCIO Record ID: 3196
The Licensor granted License of relevant know-how, patent rights and technology,for Relistor® (methylnaltrexone bromide) subcutaneous injection, to the Licensee, a leading gastrointestinal disease specialty company.
OIC is the constipation that often arises when patients take opioids for pain relief.
IPSCIO Record ID: 87659
Subject to the Right of First Refusal and Option below, Licensor shall not license to any third party, and hereby grants an exclusive option to Licensee to license, the Licensor IP Rights to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) naloxone for treatment or prevention of opioid overdose in the Territory.
Compound: Naloxone or Option Compound and any metabolite, salt, ester, hydrate, anhydride, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, complexes, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, isomer, tautomer, or optically active form of the foregoing.
Option Compound: Naltrexone and nalmephene/ nalmefene.
Naloxone is a medication used to block the effects of opioids, especially in overdose.[1] Naloxone may be combined within the same pill as an opioid to decrease the risk of misuse.
Naloxone blocks or reverses the effects of opioid medication, including extreme drowsiness, slowed breathing, or loss of consciousness. An opioid is sometimes called a narcotic.
Naloxone is used to treat a narcotic overdose in an emergency situation. This medicine should not be used in place of emergency medical care for an overdose.
Naloxone is also used to help diagnose whether a person has used an overdose of an opioid.
IPSCIO Record ID: 280326
License to Commercialize Collaboration Compounds – With respect to all Collaboration Compounds for which Licensee has received Licensors approval to develop and commercialize, Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensor’s interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.
License to Compounds (Other than Collaboration Compounds) Derived from Licensee Compounds – Licensor grants to Licensee a worldwide, perpetual, exclusive, royalty-free license, with the right to sublicense, under Licensors interest in the Collaboration IP, to exploit for any and all purposes all compounds (other than Collaboration Compounds) derived, directly or indirectly, from Licensee Compounds.
Research Licenses – The Parties hereby grant each other non-exclusive, worldwide, royalty-free research licenses, without the right to sublicense, under their respective interests in the Licensee IP, Licensor IP and Collaboration IP, in order for each Party to perform its research obligations pursuant to Research Plans during the Collaboration Term.
Collaboration Compound shall mean a Licensee Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensor Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC. A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensee or Licensor or their Affiliates to protect any compound in category (i), (ii) or (iii) above. A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above. For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensor Compound, Licensee Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound.
Joint Research Committee or “JRC†shall mean the entity organized to manage the scientific implementation of the Collaboration.
Licensor IP shall mean Licensor Patents and Licensor Know-how.
Collaboration IP shall mean Collaboration Patents and Collaboration Know-how. Collaboration IP shall not include Licensee IP or Licensor IP.
Licensee IP shall mean Licensee Patents and Licensee Know-how. Licensee IP shall not include any intellectual property owned or licensed by Licensee or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).
Licensor Patents shall mean all Patents in the Territory Controlled by Licensor or its Affiliates as the effective date, or any other Patent Controlled by Licensor during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.
Licensee Patents shall mean all Patents in the Territory Controlled by Licensee or its Affiliates as the Effective Date, or any other Patent Controlled by Licensee during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.
Collaboration Patents shall mean (i) all patents and patent applications claiming any invention or discovery which was conceived or reduced to practice during the Collaboration Term and in the course of the Collaboration, by employees or agents of Licensor, Licensee or any of their respective Affiliates, either alone or jointly (including, without limitation, the synthesis and composition of matter of any Collaboration Compound, or method of use thereof; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of the patent applications or patents in (i) above, and any substitutions, confirmations, registrations, revalidations, or additions of any of the foregoing, in each case, which is owned or Controlled, in whole or part, by license, assignment or otherwise by Licensee or Licensor during the term of this Agreement; provided, however, that Collaboration Patents shall not include any Licensor Patents or Licensee Patents.
Licensee Compound shall mean any compound brought to the Collaboration by Licensee, which is Controlled by Licensee at or after the Effective Date, and which is proprietary to Licensee by virtue of being within the Licensee IP.
Licensor Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.
The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various therapeutic areas.
IPSCIO Record ID: 203524
The New Compound shall mean a chemical entity (including salts and solvates thereof, which shall be considered the same New Compound for purposes of this Agreement) covered by any valid and unexpired claim of Licensed Patents, but shall exclude in all cases the Roberts Agreement Compound.
The New Product means a finished, formulated pharmaceutical product containing a New Compound, together with all improvements and line extensions thereon which may be included in any supplement, modification or addition to the relevant Regulatory Approval to the extent that any such improvements or line extensions contain a New Compound.
Licensee is developing alvimopan, a peripherally selective mu opioid antagonist for management of postoperative ileus, opioid induced bowel dysfunction and certain other indications. Alvimopan is in a class of medications called peripherally acting mu-opioid receptor antagonists. It works by protecting the bowel from the constipation effects of opioid (narcotic) medications that are used to treat pain after surgery.
IPSCIO Record ID: 233475
And, for the Exclusive License Grant, Licensor grants an exclusive license to use and exploit the NOS Patent Assets and the Licensors NOS Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of the NOS Inhibitor Technology and any NOS Inhibitor and the Split Dose Patent Assets and the Licensors Split Dose Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of Compound or Product using the Split Dose Technology, each solely in connection with the use of Compound and/or Product in the Territory. The exclusive license granted includes the right to grant sublicenses.
The Product shall mean any product in final form for commercial sale by prescription, over-the-counter, or by any other method, or, where the context so indicates, the product being tested in clinical trials, which contains Compound as at least one of the therapeutically active ingredients, in all final dosage forms and package configurations for any indication, or any line extension thereof.
The Compound shall mean the chemical compounds known as benzimidazole carbamate class vascular targeting agents,including those designated ANG-600 Series, whose more specific chemical names are 5 (6) substituted benzimidazole-2-carbamates, and any derivative, homolog, analog or conjugate of any of the foregoing, and any isomer, salt, hydrate, solvate, metabolite, or prodrug or the like of any of the foregoing.
The NOS Inhibitor shall mean a chemical composition that inhibits the formation or action of nitric oxide, including those disclosed in the NOS Patent Assets.
NOS Inhibitor Technology shall mean technology relating to the combination of vascular targeting agents, including Compound, and an NOS Inhibitor, including the inventions disclosed in the NOS Patent Assets.
NOS Patent Assets shall mean United States and foreign patents and patent applications, which shall be deemed to include certificates of invention and applications for certificates of invention, which as of the Effective Date or at any time during the term of this Agreement:
– are owned by Llicensor (including Licensors interest in jointly owned patents and patent applications) or which Licensor through license or otherwise has or acquires rights, and
– relate to the combination with Compound or Product of an NOS Inhibitor or the NOS Inhibitor Technology including but not limited to methods of their manufacture, methods of their use, or otherwise relate to Licensor NOS Know-How, including all certificates of invention, divisions, continuations, continuations-in-part, reissues, supplementary protection certificates or the like of any such patents and current and future patent applications.
Split Dose Patent Assets shall mean United States and foreign patents and patent applications, which shall be deemed to include certificates of invention and applications for certificates of invention, which as of the Effective Date or at any time during the term of this Agreement:
– are owned by Licensor including Licensors interest in jointly owned patents and patent applications or which Licensor through license or otherwise has or acquires rights, and
– relate to the use of Compound or Product in divided doses including but not limited to methods of their manufacture, methods of their use, or otherwise relate to Licensor Split Dose Know-How, including all certificates of invention, divisions, continuations, continuations-in-part, reissues, supplementary protection certificates or the like of any such patents and current and future patent applications.
The Split-Dose Technology shall mean a method of administering any vascular damaging agent in a divided dose, including the inventions disclosed in the Split-Dose Patent Assets.
